Hairstetics Hair Implant Device Safety and Efficacy
Safety and Efficacy Evaluation of Hairstetics Hair Implant in Subjects Affected With Hair Loss - a Clinical Study
This is a prospective, single-arm, multi-center, international, open-label, non-randomized, clinical study.
The aim of the study is to assess the safety and efficacy of the use of the Hairstetics hair implant device in subjects affected with hair loss.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Igal Ruvinsky, PhD
- Phone Number: +972-72-2501630
- Email: igal.r@hairstetics.com
Study Contact Backup
- Name: Boaz Shenhav
- Phone Number: +972-72-2501630
- Email: boaz.s@hairstetics.com
Study Locations
-
-
-
Paris, France
- Recruiting
- Cabinet du Dr G. Beilin
-
Contact:
- Ghislaine Beilin, MD
-
Paris, France
- Recruiting
- Cabinet médical du Dr Jack Smadja
-
Contact:
- Jack Smadja, MD
-
Paris, France
- Recruiting
- Georges Mandel Office Surgery Clinic
-
Contact:
- Marc Divaris, MD
-
-
-
-
-
Gurgaon, India, 122002
- Recruiting
- Paras Hospital
-
Contact:
- Anil Ganjoo, MD
-
New Delhi, India, 110088
- Recruiting
- Fortis Hospital
-
Contact:
- Manjul Agrawal, MD
-
-
-
-
-
Bucharest, Romania
- Recruiting
- Egoclinic
-
Contact:
- Irinel Nedelcu, MD
-
Bucharest, Romania
- Recruiting
- Metropolitan Hospital
-
Contact:
- Radu Jecan, MD
-
-
-
-
-
London, United Kingdom, W1G7JA
- Recruiting
- Revere clinic
-
Contact:
- Sach Mohan, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is ≥ 19 years old.
- Subject has hair loss and has chosen to undergo synthetic hair implantation.
- Subject has mental capacity to understand study guidelines and requirements (to maintain scalp hygiene, use of shampoo, delicate combing, etc.).
- Subject has been evaluated by the investigator to have a scalp condition in the planned area of implantation that is acceptable for entering the study and currently is NOT suffering from skin problems at planned implantation site or elsewhere that might affect the procedure and/or success as clinically evaluated by the investigator.
- Subject has Good general health.
- Woman of child bearing potential must have a negative pregnancy test.
- Subject willing to sign a written informed consent form (ICF) and the post implantation maintenance protocol.
Exclusion Criteria:
- Previous synthetic hair implantation or hair transplantation in the past 6 months.
- Currently suffering from skin problems at planned implantation site or elsewhere that might affect the procedure and/or success as clinically evaluated by the investigator.
- Currently receiving or have within the past 3 months received radiation- and/or chemotherapy.
- Currently using steroid product with Immunosuppressive treatment.
- Impaired coagulation.
- Serious illness that may affect subject compliance to protocol.
- Subject is using illegal drugs.
- Participating in other clinical study.
- Known allergy or hypersensitivity to Nitinol or Nickel or Titanium
- For woman: Pregnancy or breast feeding.
- Known allergy or intolerance for the prescribed antibiotics and in such a case, a different antibiotics for which the subject is not allergic or intolerance to, will be prescribed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hairstetics hair implant device
Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject.
The implantation will be carried out according to the device IFU.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Acceptable number, duration and severity of expected adverse device/procedure effects
Time Frame: 3 months following implantation
|
3 months following implantation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HET-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.